Human GRN-mutation carriers with clinically symptomatic FTD symptoms were reported to have increased plasma levels of sCD163 and CCL18, both of which are peripheral myeloid cell markers, suggesting an increase in peripheral immune activity relative to asymptomatic GRN-mutation carriers and healthy controls [98]. Here, GRN is linked to frontotemporal dementia.